Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The lower GI series market is encountering a striking rise because of the rising incidence of lower gastrointestinal problems. Conditions like colorectal disease, inflammatory bowel diseases, and diverticulitis are driving the interest for symptomatic strategies, filling the growth of the lower GI series market.
Colorectal disease screening is a significant driver in the lower GI series market. General health drives and awareness campaigns advancing normal screenings for colorectal cancer growth have prompted a surge in demonstrative techniques, including lower GI series assessments, adding to market development.
The rising geriatric population is a huge segment factor impacting the lower GI series market. With age, the risk of lower GI issues builds, prompting a developing interest for demonstrative methodology among the old population, in this way adding to market growth.
There is a striking pattern towards minimally invasive demonstrative methodology in the lower GI series market. Patients and healthcare suppliers are progressively selecting methods that proposition lower radiation openness and decreased intrusiveness while maintaining symptomatic viability.
The coordination of artificial intelligence (AI) in symptomatic imaging is a key pattern. AI calculations are being applied to lower GI series pictures for upgraded understanding and early discovery of irregularities, working on the general proficiency and precision of indicative methodology.
The reception of telemedicine and remote interviews is affecting the lower GI series market. Virtual counsels permit patients to examine side effects with healthcare experts, prompting more designated and convenient proposals for demonstrative methodology, including lower GI series tests.
There is a shift towards outpatient symptomatic administrations in the lower GI series market. Outpatient offices offer lodging, decreased waiting times, and cost-adequacy, prompting expanded patient inclination for analytic techniques outside conventional emergency clinic settings.
Progresses conversely, specialists utilized in lower GI series methodology are significant. The improvement of more secure and more compelling difference specialists upgrades the perceivability of the lower GI parcel, working on the symptomatic capacities of lower GI series assessments.
Lower GI Series Market Highlights:
Lower GI Series Market Overview
Lower GI Series Market Size was valued at USD 248.46 Billion in 2023. The Global Lower GI Series industry is projected to grow from USD 268.11 Billion in 2024 to USD 478.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.15% during the forecast period (2024 - 2032).
Lower GI series is a lower gastrointestinal series or barium enema; it is one of the medical procedure, which helps in diagnosis of diseases and abnormalities related to human large intestine and rectum. Moreover, major companies are focusing on investment in R&D to introduce efficient methods as well as innovative devices since they are under constant pressure to provide new and cost-effective methods.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 60-70 million people are affected by either major or minor GIT diseases in America. The number is continuously increasing due to poor diet and increasing aging population. The lower GI series market is driven majorly due to increasing prevalence of GI diseases, gastric cancer, and changing lifestyle. Additionally, developing technologies, increasing cost-effective methods, and the government’s support for research have boosted the growth of this market. However, availability of alternative therapies may hamper the growth of the market during the review period.
Lower GI Series Market Segmentation
The lower GI series market is segmented on the basis of by applications, types of tests, and end user.
On the basis of applications, it is segmented into gastroenteritis, colon polyps, tumor, strictures crohn's disease, ulcerative colitis, and others.
On the basis of types of test, it is segmented into double-contrast test and single-contrast test.
On the basis of end users, this market is segmented into hospitals, clinics, and laboratories.
Regional Analysis of the Lower GI Series Market
On the regional basis, the market is segmented into the America, Europe, Asia Pacific, and the Middle East & Africa. The America owns a significant share in the global market as a result of huge investment in research and development in the healthcare sector and its strong economic conditions for research and development. Increasing patient base and geriatric population to boost the growth of the Lower GI Series Market.
Europe is the second largest market followed by Asia Pacific on account of increasing technological improvements. The technological improvements will result in higher efficiency and accuracy for diagnosis. Asia Pacific is the fastest growing market due to increasing prevalence of communicable diseases in this region. India and China have started investing in research and development of healthcare sector, which will boost the Lower GI Series Market growth of this region.
Key Players in the Lower GI Series Market
Some of the key players in Lower GI Series Market are:
- Eisai (US)
- Cadila Pharmaceuticals
- PeaceHealth
- Purdue Pharma L.P.
- Alfa Wassermann
- NOVADAQ
- Mount Sinai Beth Israel
- AstraZeneca
- Ironwood Pharmaceuticals Inc.
Intended Audience
- Manufacturing industries
- Pharmaceutical industry
- Biotechnology companies
- Research and development (R&D) companies
- Government research laboratories
- Medical research institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
